Beyond Trial Dashboard

Packet Artifact

02 protocol synopsis or concept

DIAB-220 Protocol Synopsis / Concept

Training-use boundary: This is a fictional teaching artifact for clinical project-management practice. It is not a protocol, SAP, consent form, regulatory submission, SOP, validation package, or sponsor-approved record. Real study use requires medical, statistical, regulatory, quality, legal, privacy, safety, and operational review.

Administrative Information

  • Project code: DIAB-220
  • Working title: Operational anchor trial for diabetes management across active lifecycle
  • Development phase/category: Phase III
  • Study design: Randomized, controlled metabolic disease trial
  • Sponsor department: Global Clinical Trial Management Department
  • Executive sponsor: Dr. Daniel Liang
  • Medical lead: Dr. Samuel Reeves
  • Biostatistics lead: Claire Jiang
  • Clinical operations lead: Margaret "Maggie" Chen
  • Regulatory lead: Thomas Gallagher

Background And Rationale

DIAB-220 is designed to answer a project-specific clinical evidence question while teaching the operational lesson used in the book: Main lifecycle case for enrollment, retention, treatment, data cleaning, vendors, budget, and quality.

The pre-initiation assumption is that the project is scientifically plausible but operationally vulnerable. The PM team should therefore treat the synopsis as both a scientific concept and an operational risk document.

Population

Adults with type 2 diabetes inadequately controlled on standard therapy

Key feasibility questions:

  • Can sites identify eligible participants without excessive screen failure?
  • Are inclusion and exclusion criteria medically justified and operationally workable?
  • Are vulnerable-participant, caregiver, privacy, pediatric, maternal, or rare-disease considerations present?
  • Does the target population require central lab, local lab, imaging, genetic, biomarker, device, or digital screening?

Intervention Or Exposure

Investigational glucose-lowering therapy versus comparator

Operational interpretation:

  • Clinical supply, comparator, device, app, data-source, or exposure-definition assumptions must be documented.
  • Any blinding, unblinding, randomization, washout, dosing, or treatment-switch rules must be visible before initiation.
  • Vendor and site workflows must be tested against real visit flow, not only against the protocol table.

Objectives And Endpoints

  • Primary objective: Evaluate the project-specific clinical question through the primary endpoint.
  • Primary endpoint: Change in HbA1c from baseline to primary analysis visit
  • Secondary endpoints: Weight, fasting glucose, hypoglycemia, patient-reported burden, safety

Endpoint-protection questions:

  • Which visits, labs, images, devices, questionnaires, adjudication steps, or data extracts create the endpoint?
  • Which endpoint data are vulnerable to timing, missingness, site training, rater drift, central/local lab variability, vendor transfer, or participant burden?
  • Which endpoint issue would trigger governance escalation?

Study Procedures And Schedule Of Assessments

The final SOA will be owned by Medical, Clinical Operations, Biostatistics, Data Management, Safety, and Regulatory. Before initiation, the PM team requires a draft procedure map covering:

  • Screening and consent pathway.
  • Baseline assessments.
  • Randomization, exposure assignment, treatment, or data-source definition.
  • Endpoint-critical visits and windows.
  • Safety assessments and reporting triggers.
  • Sample, imaging, device, app, eCOA, EDC, IRT, or registry data flow.
  • Follow-up and closeout.

Special Operational Focus

Routine trial that becomes complex through retention, eCOA, lab, data, and budget pressures.

Initial PM Conclusion

DIAB-220 is initiation-ready only if the functional handoff packet proves that the protocol concept, endpoint protection, participant-safety pathway, vendor/system readiness assumptions, budget assumptions, and governance decision rights are mutually consistent.